NKGN(Delisted)
NKGen BiotechยทNASDAQ
--
--(--)
NKGN Profile
Nkgen Biotech, Inc.
A clinical-stage biotechnology company focused on autologous, allogeneic and CAR-NK natural killer cell therapies
3001 Daimler Street, Santa Ana, CA, 92705
--
NKGen Biotech, Inc., is a Delaware-based company. The company is a biotechnology company that develops cell therapies for neurodegenerative and tumor diseases based on activated NK cells. NK cells are part of the human innate immune response system and can selectively recognize and destroy abnormal or diseased cells. The Company's product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM cells that show higher activity compared to the starting population of NK cells, based on in vitro experimental results conducted by NKMAX, defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be mass-produced and cryopreserved while maintaining high levels of cytotoxicity and activating receptor expression after thawing and recombination.
